Fluticasone Propionate is a medium-potency synthetic corticosteroid. It is used intranasally to manage symptoms of allergic and non-allergic rhinitis, asthma and nasal polyps. It is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis. It is used orally for the treatment of asthma, eosinophilic esophagitis, Crohn’s disease and ulcerative colitis. Fluticasone propionate is also available as a combination product.
Sterling holds Certificate of Suitability n. R1-CEP 2005-268-Rev 00 issued by Quality of Medicines & HealthCare (EDQM) on 23/09/2011.
US DMF was submitted to FDA on 12/02/2003 and the following number was assigned n. 16423.
Drug product containing Sterling’s Fluticasone Propionate is commercialized in Europe and USA.